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Abstract
Background: The ERBB3 gene is essential for the proper development of the neural crest (NC) and its derivative
populations such as Schwann cells. As with all cell fate decisions, transcriptional regulatory control plays a
significant role in the progressive restriction and specification of NC derived lineages during development.
However, little is known about the sequences mediating transcriptional regulation of ERBB3 or the factors that bind
them.
Results: In this study we identified three transcriptional enhancers at the ERBB3 locus and evaluated their
regulatory potential in vitro in NC-derived cell types and in vivo in transgenic zebrafish. One enhancer, termed
ERBB3_MCS6, which lies within the first intron of ERBB3, directs the highest reporter expression in vitro and also
demonstrates epigenetic marks consistent with enhancer activity. We identify a consensus SOX10 binding site
within ERBB3_MCS6 and demonstrate, in vitro, its necessity and sufficiency for the activity of this enhancer.
Additionally, we demonstrate that transcription from the endogenous Erbb3 locus is dependent on Sox10. Further
we demonstrate in vitro that Sox10 physically interacts with that ERBB3_MCS6. Consistent with its in vitro activity,
we also show that ERBB3_MCS6 drives reporter expression in NC cells and a subset of its derivative lineages in vivo
in zebrafish in a manner consistent with erbb3b expression. We also demonstrate, using morpholino analysis, that
Sox10 is necessary for ERBB3_MCS6 expression in vivo in zebrafish.
Conclusions: Taken collectively, our data suggest that ERBB3 may be directly regulated by SOX10, and that this
control may in part be facilitated by ERBB3_MCS6.
Background
The neural crest (NC) is a transient, multipotent and
migratory population of cells present in early vertebrate
development. NC cells arise from the lateral folds of the
neural plate at neurulation and give rise to a multitude
of cell types including pigment cells, neurons and glia of
the peripheral nervous system, craniofacial skeleton and
cartilage, and adrenal medullary cells [1]. Defects in NC
development underlie several human diseases such as
Waardenburg syndrome, Hirschsrpung disease and
DiGeorge syndrome, which present a spectrum of phe-
notypes including craniofacial defects, ocular,
pigmentary and otic defects, enteric hypoganglionosis,
and cardiac malformations [2,3]. Despite significant
recent progress in the identification of key signaling
pathways and transcription factors involved in NC
induction, the hierarchical relationships between these
pathways and factors are not well understood.
One critical gene in this network is Erbb3, a receptor
tyrosine kinase that belongs to the epidermal growth
factor (EGF) receptor family. Other members of the
family include receptors such as Egfr1, Erbb2 and Erbb4
[4]. The structure of Erbb3 includes an extracellular
domain, which interacts with ligands Neuregulin1 and
Neuregulin2, and a cytoplasmic domain. Unlike other
members of the EGF receptor family, the cytoplasmic
domain of Erbb3 lacks tyrosine kinase activity [5,6].
Erbb3 is therefore thought to heterodimerize with
Erbb2, which lacks a cognate receptor but possesses
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tyrosine kinase activity, in order to activate downstream
pathways [7,8]. Upon activation, Erbb3 triggers several
downstream pathways such as PI3K, MAPK, protein
kinase C, Jak-STAT and PLCg [4].
Erbb3 plays important roles in the development of the
NC and its derivative tissues. Consistent with these
observations, expression analyses in mouse and zebrafish
have detected Erbb3/erbb3b transcripts in pre-migratory
and migratory NC, and various NC derivatives includ-
ing, cranial ganglia, posterior lateral line ganglia and
Schwann cells [9-14]. Expression has also been observed
in non-NC derived populations including the brain,
olfactory lobes and myotome [10,14]. Furthermore, mice
harbouring targeted mutant alleles of Erbb3 exhibit
defects in the formation of NC and its derivatives.
Homozygous null mice display a dramatic reduction in
numbers of Schwann cells, hypoplastic cardiac cushion
mesenchyme and cardiac valves, defects in cranial gang-
lia formation and cerebellar hypoplasia [9,13]. Erbb3
deficient mice also demonstrate a lack of chromaffin
cells in the adrenal medulla [9]. Furthermore, targeted
deletions of Nrg1 and Erbb2, a ligand and a binding
partner of Erbb3 respectively, result in NC cell migra-
tion defects [15]. More recently, several in vitro and zeb-
rafish studies have revealed a potential role for Erbb3 in
melanocyte development and in melanoma [16-18].
Consistent with these data, Erbb3 has been implicated
in other neoplasias including breast cancer and lung
cancer [19]. However, what factors act upstream of
Erbb3 to direct its expression and function in the variety
of cell types derived from NC cells is not well under-
stood. Even less well understood is the genomic
sequence basis of the transcriptional regulatory control
that facilitates the cell fate decisions and homeostatic
maintenance of these cells during development
One factor proposed to regulate Erbb3 is Sox10, a
member of the SoxE family of transcription factors [20].
Sox10 is indispensible for proper neural crest develop-
ment and loss of Sox10 leads to reductions of specific
NC derivatives including peripheral neurons and mela-
nocytes [21,22]. Also, SOX10 mutations have been dis-
covered in several patients with Waardenburg syndrome
and syndromic Hirschsprung disease [23]. However,
data generated to date linking Sox10 and Erbb3 have
been largely correlative. Both Sox10 and Erbb3 share
overlapping expressions patterns and deletions of Sox10
and Erbb3 affect overlapping cell populations such as
Schwann cells, cranial ganglia and sympathetic neurons.
In mice where the endogenous Sox10 locus has been
replaced by a LacZ cassette, Erbb3 expression is initiated
in premigratory NC but is lost once the cells begin
migrating [10], suggesting Erbb3 regulation by Sox10.
Furthermore Erbb3 transcript levels increase upon over-
expression of Sox10 in Neuro2A neuroblastoma cells
[10]. However, it is not known if this regulation is direct
or indirect because the regulatory topography of Erbb3
has not yet been uncovered, and nor have any Sox10
responsive elements been demonstrated at the Erbb3
locus.
In this study, we address the transcriptional regulation
of ERBB3 during neural crest development. We use
sequence constraint as a metric predictive of function to
identify putative regulatory elements at the human
ERBB3 locus. We test the regulatory potential of these
elements in vitro in two cell lines representative of
neural crest derived tissues. We also test each element
for epigenetic marks consistent with enhancer activity.
We verify enhancer activity of each element in vivo
using zebrafish transgenesis, identifying three transcrip-
tional enhancers of ERBB3. One intronic enhancer
termed ERBB3_MCS6 displays the strongest enhancer
activity in vitro and high enrichment for H3K4me1. We
demonstrate that this enhancer is responsive to and
dependent on Sox10 for its regulatory behaviour. Simi-
larly, we demonstrate that Sox10 is necessary and suffi-
cient for activation of the endogenous Erbb3.
Furthermore, we also demonstrate that ERBB3_MCS6
directs expression in NC cells and their derivative
lineages in vivo in zebrafish, and that the requirement
for Sox10 for its regulation is maintained in vivo as well.
Therefore, we conclude that SOX10 likely contributes to
the transcriptional modulation of ERBB3 acting at least
in part directly via ERBB3_MCS6.
Results
Multi-species conserved sequences (MCS) at the ERBB3
locus direct reporter expression in Erbb3 expressing cell
lines and show epigenetic marks consistent with
enhancer activity
As in previous studies, we used sequence constraint to
identify putative regulatory enhancers of ERBB3 [24,25].
Briefly, we identified evolutionarily conserved non-cod-
ing sequences at the human ERBB3 locus using Phast-
cons (http://genome.ucsc.edu/) [26], selecting eight
sequences for functional analyses (LOD 30-196; Meth-
ods; Figure 1A). We amplified and cloned each of the
sequences upstream of an E1B minimal promoter driv-
ing a luciferase reporter. We tested the regulatory
potential of each of the sequences to drive transcription
via luciferase assays in two NC derived cell lines, cul-
tured mouse melanocytes (melan-a) and cultured rat
Schwann cells (S16), both of which express Erbb3 (Fig-
ure 1B, C). Of the eight MCS elements amplified and
tested, five (ERBB3_MCS2, MCS3, MCS4, MCS6 and
MCS7) directed luciferase reporter expression at levels
significantly higher than the promoter only luciferase
construct in both cell lines (p≤0.003) (Figure 1B, C).
Furthermore, ERBB3_MCS6 showed the greatest
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increase in luciferase activity- approximately 23-fold
greater than the promoter only construct (p = 0.002) in
melan-a cells and approximately 150-fold greater than
the promoter only construct in S16 cells. Interestingly,
although ERBB3_MCS5 overlaps ERBB3_MCS4, it
demonstrates lower luciferase activity than MCS4 in
melan-a cells. This suggests that there may be transcrip-
tional repressor elements in ERBB3_MCS5 that are
causing it to drive lower reporter expression in the luci-
ferase assay. When the eight ERBB3_MCS elements
were tested in a cell line that does not express Erbb3
(NIH3T3), none directed higher luciferase activity than
the promoter only construct (Figure 1D). Therefore, this
suggests that ERBB3_MCS 2, MCS3, MCS4, MCS6 and
MCS7 are potentially enhancers of ERBB3 expression in
the NC.
In order to determine whether these MCS elements
were indeed enhancers within their genomic context, we
assayed the presence of an epigenetic mark previously
shown to be predictive of enhancer function. Since
H3K4 monomethylation (H3K4me1) has been shown to
be enriched at transcriptional enhancers, we used chro-
matin immunoprecipitation (ChIP) to determine
whether H3K4me1 marks were enriched at the mouse
orthologs of ERBB3_MCS elements within the genomic
context of melan-a cells [27]. We used an antibody
against H3K4me1 and an isotype control IgG to immu-
noprecipitate sheared crosslinked chromatin from these
Figure 1 Multi-species conserved sequences at the ERBB3 drive reporter activity in neural crest derived lines and exhibit epigenetic
marks consistent with enhancer activity. (A) Schematic representation of the eight multi-species conserved sequences at the human ERBB3
locus. (B) Luciferase activity of ERBB3_MCS1-8 in melan-a cells. (C) Luciferase activity of ERBB3_MCS1-8 in S16 cells. (D) Luciferase activity of
ERBB3_MCS1-8 in NIH3T3 cells. All luciferase values are normalized to internal renilla control and are shown as fold-change in reporter activity as
compared to the promoter only construct (pe1b) with standard deviation. (E) Real-time PCR results of Chromatin Immunoprecipitation. Black bar
indicates enrichment upon H3K4me1 ChIP whereas grey bar indicates enrichment with non-specific IgG. Error bars indicate standard deviation of
technical replicates in real-time PCR. Elements MCS1-8 represent the mouse orthologs of ERBB3_MCS elements. C refers to a region 3 Mb
upstream of Erbb3, which was used as a negative control.
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cells. We analyzed immunoprecipitation using real-time
PCR and calculated enrichment using the percent input
method (Figure 1E). ERBB3_MCS1, MCS2 and MCS3
showed consistently low levels of enrichment upon
immunoprecipitation with the H3K4me1 antibody as
compared to the IgG control samples, whereas
ERBB3_MCS4, MCS5, MCS6, MCS7 and MCS8 showed
consistently high levels of enrichment upon immunopre-
cipitation as compared to the IgG samples. A control
sequence 3 Mb upstream of ERBB3 was not enriched in
H3K4me1 samples as compared to IgG samples.
ERBB3_MCS5, MCS7 and MCS8 showed the highest
levels of enrichment as compared to the IgG samples.
This contrasts with the low luciferase activity driven by
these sequences in vitro, consistent with reports suggest-
ing that H3K4me1 is not sufficient to distinguish
between functionally active and inactive enhancers
[28,29]. Elements ERBB3_MCS2, MCS3, MCS4 and
MCS6 however did show increased luciferase activity as
well as H3K4me1 marks, suggesting that these
sequences may be functional endogenous enhancers of
ERBB3 in NC-derived cell types.
ERBB3_MCS6 harbours putative transcription factor
binding sites for key neural crest transcription factors
Since ERBB3_MCS6 demonstrated the highest luciferase
activity in vitro and showed enrichment for H3K4me1
consistent with a role for ERBB3_MCS6 as an enhancer
of ERBB3, we focused our subsequent analyses on this
element. To determine what pathways or transcription
factors may be acting upon this element and hence
potentially modulating Erbb3 expression, we queried
three publicly available transcription factor identification
databases (JASPAR, MATCH and TRANSFAC) to iden-
tify putative transcription factor binding sites (TFBSs)
within this sequence. To refine our search further we
prioritized sites that were found by two or more TF
databases, selecting those that corresponded to tran-
scription factors with known roles in NC development
(SOXE and AP2). We identified two SOXE sites (SOXE-
1 and SOXE-2) and one AP2 site (Additional file 1, Fig-
ure S1). Members of the SOXE family, SOX8, SOX9
and SOX10, bind to the SOXE consensus site 5’-
AACAAT-3’. The identification of SOXE family (SOX8,
SOX9 and SOX10) motifs is consistent with the pre-
dicted role for Sox10 in Erbb3 modulation. SOXE pro-
teins typically bind the consensus site 5’-AACAAT-3’.
Both SOXE-1 and SOXE-2 contain the 5’-ACAAT-3’
core sequence but differ from the consensus in that the
5’-most adenine is replaced by a cytosine. AP2 is a reti-
noic acid inducible transcription factor that binds to the
consensus sequence 5’-CCCCAGGC-3’ [30,31]. It is
expressed in the NC and its derivatives including cranial
and sensory ganglia and facial mesenchyme and has a
known role in the regulation of ERBB3 expression
[32-36]. The ERBB3 promoter harbours potential AP2
binding sites, causing speculation of the role of AP2 as
an ERBB3 regulator [37].
SOXE2 is required for enhancer activity of ERBB3_MCS6
We set out to determine the importance of the SOXE
and AP2 transcription factor families in modulating the
activity of ERBB3_MCS6 by mutating predicted binding
sites in the context of a pe1b promoter driving a lucifer-
ase reporter. We then compared the luciferase activity
of each mutant construct to that of the wild-type
ERBB3_MCS6 sequence in the melan-a cell line, which
expresses Sox10, Erbb3 and Ap2 (Figure 2A). Mutation
of the SOXE2 but not the SOXE1 motif significantly
reduced enhancer activity of ERBB3_MCS6 (Figure 2A,
p = 0.002 for SOXE2). This observation is consistent
with a suggested role for Sox10 in regulating Erbb3 in
NC-derived populations [10]. However, since mutation
of the SOXE-2 site does not completely abrogate
ERBB3_MCS6, this suggests that additional factors may
also be responsible for the activity of ERBB3_MCS6. By
contrast, mutation of the AP2 site does not significantly
reduce luciferase activity of ERBB3_MCS6 across repli-
cate experiments. However, we cannot exclude the pre-
sence of a non-canonical AP2 site that may be required
for ERBB3_MCS6 activity independent of or in addition
to this site.
Sox10 is necessary for ERBB3_MCS6 enhancer activity and
Erbb3 expression
Since mutation of the SOXE-2 binding site caused a sig-
nificant reduction in ERBB3_MCS6 enhancer activity,
we asked whether Sox10 may be acting through
ERBB3_MCS6 to regulate Erbb3 in NC populations. We
used siRNA (SMARTpool, Dharmacon) to transiently
knock down Sox10 gene product in melan-a cells and
assayed the effect of the knockdown on ERBB3_MCS6
activity via luciferase assays, as before. Consistent with
significantly reduced ERBB3_MCS6 activity (Figure 2B;
p = 0.05). Sox10 knockdown was confirmed via Western
blot as shown in Figure 2C. We also determined the
effect of Sox10 knockdown on endogenous Erbb3 pro-
tein levels in melan-a cells. As shown in figure 2D,
knockdown of Sox10 causes a decrease of endogenous
Erbb3 protein levels. Similarly, we interfered with Sox10
protein function in S16 cells using a previously charac-
terized construct expressing a dominant negative mutant
form of Sox10 (E189X) under the control of a CMV
promoter [38]. The E189X mutant protein has an intact
DNA binding domain but lacks a transactivation
domain. Upon transfection of S16 cells with this mutant
cDNA of Sox10, there was a significant decrease in luci-
ferase activity of ERBB3_MCS6 (Figure 2E). Taken
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Figure 2 Sox10 is necessary and sufficient for the activity of ERBB3_MCS6 in vitro. (A) Luciferase activities of wild-type ERBB3_MCS6 and
TFBS mutations in ERBB3_MCS6 in melan-A cell line. The position of each TFBS in ERBB3_MCS6 is shown on top and the corresponding
mutation in each TFBS is shown next to the luciferase value for that construct. * indicates statistical significance. (B) Luciferase activity of WT
ERBB3_MCS6 in melan-A cells in mock-transfected cells and in cells with transient Sox10 and Ap2 knockdown. (C) Western blot to confirm
knockdown of Sox10 and Ap2 protein upon siRNA treatment. Tubulin antibody was used as a loading control. (D) Western blot showing Erbb3
protein levels in melan-a cells upon transient transfection with Sox10 and Ap2 siRNA or mock-transfected cells. Tubulin antibody was used as a
loading control. (E) Luciferase activity of ERBB3_MCS6 upon knockdown of Sox10 in S16 cells using a dominant negative SOX10 mutant (E189X)
under a CMV prmoter. (F) Luciferase assay of WT and SOXE-2m ERBB3_MCS6 in Neuro2A cells when transiently co-transfected with an empty
expression vector (pcDNA.31) and Sox10 cDNA. Cell lysates were collected 24 hours post transfection. (G) Luciferase assay of WT ERBB3_MCS6 in
Neuro2A cells when transiently co-transfected with equal amounts of WT and Sox10-ΔSTP cDNA either individually or in combination. Cell lysates
were collected 24 hours post transfection. All luciferase values are normalized to renilla internal control and shown as fold-change compared to
promoter only construct (pe1B) with standard deviation. (H) Real-time PCR of Erbb3 transcript levels upon expression of WT and Sox10-ΔSTP
cDNA individually and in combination. Values are normalized to 18s internal control and are shown as fold-change compared to promoter only
construct (pcDNA3.1) with standard error. (I) Real-time PCR of ChIP against Sox10 in untreated S16 cells and in S16 cells treated with Sox10
morpholino. Black bar indicates enrichment upon Sox10 ChIP whereas grey bar indicates enrichment with non-specific IgG. Error bars indicate
standard deviation of technical replicates in real-time PCR.
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together, these experiments demonstrate that Sox10 is
necessary for the expression of Erbb3 and for enhancer
activity of ERBB3_MCS6, consistent with its predicted
role in modulating Erbb3. Knockdown of Ap2 in melan-
a cells also led to a significant reduction in
ERBB3_MCS6 transcriptional activity (Figure 2B).
Furthermore, Ap2 knockdown also reduced endogenous
Erbb3 protein levels (Figure 2D), consistent with pre-
vious evidence for a role for AP2 in regulating ERBB3
[35,36].
Sox10 is sufficient for ERBB3_MCS6 enhancer activity and
Erbb3 expression
Given that Sox10 is necessary for ERBB3_MCS6 enhan-
cer activity, we next tested whether Sox10 is also suffi-
cient for ERBB3_MCS6 activity. We transiently co-
transfected mouse neuroblastoma cells (Neuro2A) with
the ERBB3_MCS6 luciferase vector and with either a
construct expressing wild-type Sox10 cDNA under the
control of a CMV promoter (pcDNA3.1) or with an
empty expression vector. Neuro2A cells were selected
due to low expression levels of Sox10 and Erbb3 and
because this cell line has been previously used to study
the interaction between Sox10 and Erbb3 [10]. In the
presence of Sox10, the transcriptional activity of
ERBB3_MCS6 increased almost 25-fold, compared to
cells co-transfected with the empty vector (Figure 2F).
In the absence of Sox10, ERBB3_MCS6 does not display
significant transcriptional activity in Neuro2A cells.
Further, consistent with a role for Sox10 in directly reg-
ulating MCS6, mutation of the SOXE-2 site abrogates
the increase in transcriptional activity. Similar results
were also seen when human SOX10 cDNA was used in
co-transfection experiments in NIH3T3 cells (Additional
file 2, Figure S2). On the other hand, AP2 was unable to
significantly transactivate ERBB3_MCS6 in NIH3T3
cells (Additional file 2, Figure S2). Also, when added in
combination with SOX10, it was unable to increase tran-
scriptional activity of ERBB3_MCS6 in a manner that is
more than additive when compared to SOX10 and AP2
independent transactivation, further suggesting that AP2
and SOX10 do not interact to regulate ERBB3_MCS6.
To further investigate the role of Sox10 in regulating
ERBB3_MCS6, we next determined whether established
disease causing mutations in Sox10 might in part med-
iate their regulation of Erbb3 via ERBB3_MCS6. To this
end, we used a Sox10 mutant cDNA expression con-
struct (c.928_929ins), hereby referred to as Sox10-ΔSTP
to transactivate ERBB3_MCS6. This mutant was first
discovered in the Dom mouse model of Hirschsrpung
disease [20,21] and has a single nucleotide (Guanine)
insertion at nucleotide 929 of the coding sequence, lead-
ing to a translational frameshift. The resulting protein
possesses an intact DNA binding domain but 99 novel
nucleotides replace the putative activation domain. The
resulting protein inhibits the activity of wild-type Sox10
in a dominant negative fashion. Co-transfection of
ERBB3_MCS6 with Sox10-ΔSTP does not result in
ERBB3_MCS6 activity (Figure 2G). Additionally, ΔSTP
also compromises the transactivation of ERBB3_MCS6
by wild-type Sox10 as seen in cells co-transfected with
both the wild-type and the mutant forms of Sox10. This
implies that ERBB3_MCS6 plays an important role in
the regulation of Erbb3 by Sox10.
If ERBB3_MCS6 were indeed an important link in the
regulation of Erbb3 expression by Sox10, we would
expect the overexpression of wild-type Sox10, but not
the Sox10-ΔSTP mutant, to increase endogenous tran-
script levels of Erbb3. In fact, when we examined the
levels of Erbb3 transcript in Neuro2A cells upon Sox10
overexpression, we found that it was seven-fold higher
than Erbb3 transcript levels in the absence of Sox10
(Figure 2H). Furthermore, Sox10-ΔSTP was unable to
increase Erbb3 transcript levels and it also impeded the
ability of the wild-type protein to increase Erbb3 tran-
script levels. An increase in total Sox10 transcript levels
upon overexpression was verified via real-time PCR
(Additional file 3, Figure S3). Therefore, this implies
that Sox10 is sufficient for the transcriptional activation
of Erbb3.
Sox10 physically binds ERBB3_MCS6
We next used electrophoretic mobility shift assays to
determine if ERBB3_MCS6 physically binds protein in a
manner dependent on the SOXE-2 motif. We generated
50 bp probes that span the SOXE-2 binding site and
labeled the probes with biotin. We then incubated the
probes with nuclear extract derived from melan-a cells
and subjected the reactions to gel electrophoresis. As
seen in Additional file 4, Figure S4, a factor in the
melan-a nuclear extract bound the probe and retarded
its migration in the gel, causing a shift. This binding
was successfully competed away by using increasing
amounts of unlabeled probe. To determine whether this
binding was specific to the SOXE-2 binding site, we
next mutated the SOXE-2 binding site and incubated
unlabeled mutant probe with nuclear extract. As is seen
in lane 5 of Additional file 4, Figure S4, the mutant cold
probe was unable to compete away the binding, thus
indicating that the gel shift seen is specific to binding at
the SOXE-2 binding site. In order to assay whether
Sox10 directly binds to ERBB3_MCS6, we used chroma-
tin immunoprecipitation followed by quantitative PCR
using an antibody directed against Sox10 in S16 cells.
As shown in Figure 2I, the rat ortholog of
ERBB3_MCS6 is enriched in Sox10 immunoprecipitated
samples but not in IgG immunoprecipitated samples.
This binding is specific to Sox10 as knocking down
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Sox10 protein levels in S16 via siRNAs caused a loss of
enrichment of ERBB3_MCS6 upon Sox10 immunopreci-
pitated in these cells. Collectively, this implies that
Sox10 directly binds ERBB3_MCS6.
ERBB3_MCS6 directs reporter expression in a neural crest
specific manner reminiscent of erbb3b expression in
zebrafish
In order to confirm that ERBB3_MCS6 is an enhancer
of ERBB3 in vivo, we generated stable transgenic zebra-
fish lines of ERBB3_MCS6 driving an eGFP reporter
using a Tol2 based zebrafish transgenesis assay [39].
Briefly, we cloned ERBB3_MCS6 upstream of a cfos
minimal promoter driving enhanced green fluorescent
protein (eGFP). We then injected this sequence into 1-2
cell zebrafish embryos, screened G0 embryos for vector
integration, and evaluated their offspring for germ line
reporter expression. Reporter expression was assayed in
four independent transgenic lines and compared to pre-
viously published patterns of endogenous Erbb3/erbb3b
expression [10-12,14]. Consistent with its strong in vitro
regulatory potential, ERBB3_MCS6 drove reporter
expression in NC populations as early as 24 hours post
fertilization (hpf) in transgenic zebrafish in a manner
reminiscent of erbb3b expression (Figure 3A, B). Expres-
sion was noted in cranial neural crest, migratory and
pre-migratory crest, all regions where Erbb3/erbb3b is
known to be expressed (Figure 3A, B) [11]. At 48 hpf,
expression was noted in the dorsal root ganglia, poster-
ior lateral line ganglia and in Schwann cell precursors,
consistent with known Erbb3/erbb3b expression (Figure
3C) [12,13]. Finally, at 72 hpf expression was noted in
cells that are consistent in shape and position with
mature oligodendrocytes (Figure 3D) [40]. Therefore,
ERBB3_MCS6 drives reporter expression in vivo in
neural crest cells and its derivative tissues in a manner
consistent with erbb3b expression. Two other sequences,
ERBB3_MCS1 and MCS4 also drove consistent expres-
sion in multiple founders in NC-derived populations
consistent with Erbb3/erbb3b expression (Additional file
5, Figure S5). Although ERBB3_MCS1 did not show sig-
nificant enhancer activity in vitro, or H3K4me1 marks,
it demonstrated expression in vivo in a manner consis-
tent with Erbb3 expression. This sequence directed
reporter expression starting at 48 hpf in the mesence-
phalon, olfactory bulbs, cranial ganglia and pharyngeal
arches, all regions of demonstrated Erbb3 expression
[14,41]. ERBB3_MCS1 also directed expression in the
midbrain-hindbrain boundary and in the hindbrain,
regions where Erbb3 function has been shown to be
essential [9] (Additional file 5, Figure S5A, B, C).
Furthermore, this element directed expression in cells
lining the anterior lateral line neurons and the epiphysis
(data not shown). Consistent with its strong in vitro
regulatory potential and H3K4me1 marks,
ERBB3_MCS4 directed reporter expression in vivo.
ERBB3_MCS4 drove eGFP expression in vivo, beginning
at 24 hpf in the mesencephalon, the hindbrain and the
pharyngeal arches. It also directed expression in the
myotome consistent with endogenous Erbb3 expression
[10,11] (Additional file 5, Figure S5D, E, F). This sug-
gests that ERBB3_MCS1, MCS3 and MCS6 are all NC-
directed enhancers of ERBB3.
SOXE-2 motif is necessary for the activity of ERBB3_MCS6
in vivo in zebrafish
To determine the contribution of the SOXE-2 motif to
the proper expression of ERBB3_MCS6 in vivo, we gen-
erated stable transgenic zebrafish lines with
ERBB3_MCS6 harbouring a mutation in the SOXE-2
motif. We identified three independent stable transgenic
zebrafish lines with the SOXE-2m ERBB3_MCS6 con-
struct directing eGFP expression. eGFP expression was
inconsistent among these lines. This may either be a
direct result of position effect based on the position of
integration of the vector, or mutation of the SOXE-2
motif may make the sequence more amenable to posi-
tion effect due to loss of proper regulatory control. In
one of the three lines, eGFP expression was not seen at
24 hpf whereas in the remaining two lines eGFP expres-
sion was qualitatively similar to expression directed by
the WT ERBB3_MCS6 construct at 24 hpf (Figure 3E,
F). Additionally, mutation of this site may yield quanti-
tative differences in eGFP expression between the WT
and mutant constructs. Technical reasons such as varia-
tion in transgene copy number and position effect pre-
clude the use of this assay to evaluate such differences.
Therefore, we cannot exclude the possibility that addi-
tional elements within ERBB3_MCS6 may be sufficient
for its expression in NC in the early embryo. However,
at 48 hpf and 72 hpf, expression driven by the mutant
construct was qualitatively different across all founders
as compared to expression directed by the WT con-
struct. Expression was lost from dorsal root ganglia cells
and Schwann cells in 48 hpf SOXE-2m ERBB3_MCS6
transgenic embryos. Expression domains were gained
within these mutants in the notochord and cells of the
ventral spinal cord (Figure 3G and data not shown).
Furthermore, at 72 hpf expression was not seen in oligo-
dendroglial cells in SOXE-2m ERBB3_MCS6 transgenic
embryos (Figure 3H). However, at both 48 hpf and 72
hpf, expression in the ectomesenchymal derivatives of
the NC such as in the pharyngeal arches was maintained
in the mutant transgenic fish (data not shown). This is
in agreement with a known role for Sox10 in non-ecto-
mesenchymal but not in ectomesenchymal NC popula-
tions in the zebrafish [42]. This suggests that additional
elements within ERBB3_MCS6 are sufficient for the
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expression of this sequence in ectomesenchymal deriva-
tives of the NC. Therefore, the SOXE-2 motif is impor-
tant for the proper expression of ERBB3_MCS6 in non-
ectomesenchymal neural crest derivatives such as dorsal
root ganglia and Schwann cells, but not in premigratory
and migratory crest cells or ectomesenchymal NC
derivatives. However, based on the diminution and not
complete abrogation of ERBB3_MCS6 activity in vitro,
we expect that mutation of this site may produce quan-
titative effects on the expression of ERBB3_MCS6,
which cannot be assayed by zebrafish transgenesis.
Therefore, to address the role of Sox10 in regulation
Figure 3 ERBB3_MCS6 drives reporter expression in vivo in a pattern similar to erbb3b and under the control of sox10. (A-D) Expression
pattern of ERBB3_MCS driving eGFP in G1 transgenic 24-72hpf zebrafish embryos. Arrows indicate tissues where expression was noted in
multiple founders. (E-H) eGFP expression pattern seen in multiple founders of SOXE-2m ERBB3_MCS6 transgenic fish. Although expression is
similar to WT ERBB3_MCS6 at 24hpf, expression differs at later stages of development. (I-P) Results of morpholino knockdown of sox10 in
ERBB3_MCS6 transgenic embryos. (I-L) Normal expression of ERBB3_MCS6 in uninjected transgenic embryos at 24-48hpf. (M-P) Loss of reporter
expression in embryos injected with a Sox10 morpholino at 24hpf and appearance of disorganized GFP expressing NC cells at 48hpf.
Abbreviations: cranial neural crest (CNC), migratory crest (MC), pre-migratory crest (PMC), dorsal root ganglia (DRG), posterior lateral line (PLL),
Schwann cells (SC), oligodendrocytes (OD) and notochord (NC).
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ERBB3_MCS6 in vivo, we used morpholinos analysis in
zebrafish.
sox10 is necessary for the activity of ERBB3_MCS6 in vivo
in zebrafish
In order to determine whether Sox10 is required for the
enhancer activity of ERBB3_MCS6 in vivo similar to its
requirement in vitro, we used morpholinos against
sox10 in the stable transgenic ERBB3_MCS6 zebrafish to
assay the effect of sox10 depletion on ERBB3_MCS6
activity. Using a previously published translation-block-
ing morpholino against the zebrafish sox10 gene pro-
duct, we knocked down levels of sox10 in the
ERBB3_MCS6 transgenic zebrafish [43]. Depletion of
sox10 in zebrafish produces a phenocopy of the colour-
less (sox10-/-) zebrafish mutant phenotype, which has
been studied in detail [42]. Although NC cells form
upon sox10 depletion, they accumulate in the premigra-
tory position and fail to migrate and differentiate appro-
priately into their subsequent lineages [42,43]. Thus, if
sox10 were necessary for ERBB3_MCS6 expression, we
would expect to see a loss of ERBB3_MCS6 driven
reporter expression in premigratory NC as well as a
subsequent loss of expression in NC derived cell types
such as Schwann cells and DRG due to the loss of these
populations. Consistent with our expectation, upon
knocking down sox10, we noted a complete loss of
ERBB3_MCS6 activity in the developing NC in one-day
old embryos (Figure 3N,O). This is in sharp contrast to
the ERBB3_MCS6 driven reporter expression seen in
the premigratory and migratory NC of uninjected
embryos (Figure 3J,K). Since the sox10 morpholino pro-
duces embryos with a range of phenotypes, in embryos
that show a weaker phenotype, we noticed a reduced
number of eGFP expressing premigratory NC cells and
highly reduced numbers of migrating crest at 24 hpf,
consistent with a role for Sox10 in regulation
ERBB3_MCS6 (Additional file 6, Figure S6C, D). eGFP
expression in the cranial NC was affected to a lesser
degree in these embryos (Additional file 6, Figure S6C).
However, eGFP expression in 24 hpf embryos was noted
in only 6/130 injected embryos (4.6%), which is in sharp
contrast to the 27/60 uninjected (45%) embryos that
showed eGFP expression at 24 hpf. By 48 hpf,
ERBB3_MCS6 driven eGFP expression was noted in
morpholino injected embryos in cells that are consistent
in position with premigratory NC (Figure 3P). Expres-
sion was also noted in some migratory NC, however,
these cells are highly disorganized as compared to the
eGFP expressing cells seen in uninjected embryos con-
sistent with migratory crest previously described for this
model (Figure 3L, P) [42,43]. eGFP expression persists
in these non-migrating NC cells upto 96hpf (data not
shown) but is not seen in NC derived cells. Therefore,
this suggests that sox10 is necessary for the timely and
proper expression of ERBB3_MCS6 in neural crest cells
and its derivative lineages in vivo in zebrafish.
Discussion
Although ERBB3 is an important gene in the develop-
ment and differentiation of a range of NC-derived popu-
lations, not much is known about the sequences and
factors modulating its transcriptional output. Sox10,
however, has been shown to influence Erbb3 levels [10],
although, whether this regulation is direct or indirect
was unknown. In this study, we identify novel regulatory
enhancers of ERBB3 that direct expression in NC
derived cell lines and exhibit epigenetic marks consistent
with enhancer activity. One of these enhancers,
ERBB3_MCS6 directs the strongest reporter expression
in vitro and a broad overlap with endogenous erbb3b
expression in vivo in zebrafish. We demonstrate that
ERBB3_MCS6 is dependent upon and is responsive to
Sox10 both in vitro and in vivo. Furthermore, we also
demonstrate that Sox10 is both necessary and sufficient
in vitro for endogenous Erbb3 expression. Finally, we
demonstrate that Sox10 physically binds to
ERBB3_MCS6, suggesting that SOX10 mediates its effect
on ERBB3, at least in part, directly through
ERBB3_MCS6.
Using a combination of sequence constraint, in vitro
luciferase and chromatin immunoprecipitation assays,
and in vivo zebrafish transgenesis, we have identified
three functional enhancers of ERBB3- ERBB3_MCS1,
MCS4 and MCS6. Although ERBB3_MCS1 did not sig-
nificantly drive luciferase activity in vitro or exhibit
enrichment of H3K4me1 marks, it drove reporter
expression in transgenic zebrafish embryos in a manner
consistent with endogenous erbb3b expression. Further-
more, although elements ERBB3_MCS2, MCS3 and
MCS7 showed increased luciferase activity in vitro, they
did not exhibit NC-directed enhancer activity in vivo.
This suggests that although in vitro assays are useful in
assaying the regulatory potential of enhancer sequences,
they represent a single stage and cell type in develop-
ment as compared to the full spectrum of NC deriva-
tives that can be assayed in vivo and can potentially
overlook regulatory sequences, which may be active at
different stages or cell types or may attribute activity to
sequences that are not biologically functional. Similarly,
comparison of H3K4me1 marks and enhancer activity in
the elements tested demonstrates that H3K4me1 is not
sufficient to distinguish between active and inactive
enhancers. ERBB3_MCS5, MCS7 and MCS8 showed
very high levels of H3K4me1, but did not direct tran-
scriptional activity in vitro or in vivo, suggesting that
additional epigenetic or transcriptional marks may be
necessary to distinguish them from active enhancers.
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These data are consistent with recent reports that sug-
gest that additional epigenetic marks such as H3K27ac
may be necessary to distinguish between H3Kem1
marked active and poised enhancers [28,29].
The intronic enhancer ERBB3_MCS6 demonstrated
high transcriptional activity in vitro and also exhibited
H3K4me1 marks. Furthermore, it directed expression
almost exclusively, and broadly, in developing NC popu-
lations. The role of AP2 in regulating ERBB3_MCS6
remains unclear. Mutation of the AP2 binding site does
not significantly reduce transcriptional activity of
ERBB3_MCS6, suggesting that it is not required for the
activity of ERBB3_MCS6. Furthermore, ectopic expres-
sion of AP2 does not increase transcriptional activity of
ERBB3_MCS6 (Additional file 2, Figure S2). However,
knockdown of Ap2 caused a significant decrease in tran-
scriptional activity of ERBB3_MCS6 (Figure 2B). There-
fore, although AP2 may be necessary for the activity of
ERBB3_MCS6, it is not sufficient for transcriptional
activity of ERBB3_MCS6, suggesting that it may act in
concert with other transcription factors to mediate its
effect on ERBB3_MCS6. Based on the results of our
assays, it does not seem that AP2 interacts with SOX10
to regulate ERBB3_MCS6, although we cannot exclude
the possibility that the contribution of AP2 to the regula-
tion of ERBB3_MCS6 may be rate limited by and second-
ary to regulation by SOX10. Therefore, further
examination will be required to determine how AP2 may
regulate ERBB3_MCS6 and what, if any, co-factors may
mediate this regulation. Since AP2 is known to regulate
ERBB3, it is not surprising that we see a decrease in
Erbb3 protein levels upon Ap2 knockdown in melan-a
cells [35,36], however whether this decrease is mediated
in part via ERBB3_MCS6 will require further investiga-
tion. Similarly, it will also be interesting to determine
what, if any, other TFs may be involved in regulating
ERBB3 via ERBB3_MCS6 by expanding the search for
functionally important sequence motifs therein.
However, by focusing our investigation on the role of
SOX10 in regulating ERBB3_MCS6, we show that it is
directly responsive to SOX10. Although there were two
potential Sox10 binding sites in ERBB3_MCS6, only one
of them, SOXE-2 was required in our in vitro assays.
This site is perfectly conserved across mammals and
mutation of the site causes a loss of Sox10 responsive-
ness of ERBB3_MCS6. Furthermore, mutation of the
SOXE-2 site affects the expression of ERBB3_MCS6 in
non-ectomesenchymal NC derivatives in zebrafish, but
not in ectomesenchymal derivatives of NC or in early
premigratory and migratory NC. Although quantitative
differences in expression of ERBB3_MCS6 due to the
SOXE-2 mutation cannot be ruled out as they are below
the threshold of detection by the zebrafish transgenesis
assay, this data suggests that other motifs within
ERBB3_MCS6 may be sufficient for its expression in
early NC and ectomesenchymal derivatives. However,
using additional in vitro and in vivo assays, we estab-
lished an important role for Sox10 in regulating
ERBB3_MCS6 via the SOXE-2 motif. Knockdown of
Sox10 abrogates ERBB3_MCS6 activity, whereas ectopic
expression of Sox10 induces ERBB3_MCS6 response,
demonstrating that Sox10 is both necessary and suffi-
cient for ERBB3_MCS6 transcriptional activity. Similarly,
we also show that Sox10 is both necessary and sufficient
for Erbb3 expression. This is consistent with previous
data suggesting that Erbb3 is under the control of Sox10
[10]. Using gel-shift and chromatin immunoprecipitation
assays, we also demonstrate direct binding of Sox10 to
ERBB3_MCS6, most likely mediated through the SOXE-
2 site. Finally, we use morpholino analysis in
ERBB3_MCS6 transgenic zebrafish to demonstrate a
requirement for Sox10 in the proper expression of this
enhancer. Therefore, our data suggest that
ERBB3_MCS6 may play a critical role in mediating the
regulation of ERBB3 by SOX10.
Conclusions
In conclusion, we have identified three transcriptional
enhancers at the ERBB3 locus, whose expression
domains overlap NC-derived populations. We show that
one such enhancer (ERBB3_MCS6) directs reporter
expression broadly in NC cells and, like ERBB3, is
directly responsive to Sox10, implying that Sox10 may
act through this enhancer to regulate ERBB3 transcrip-
tion in the NC.
Methods
Fish husbandry and transgene and morpholino injections
Zebrafish were bred and maintained as previously
described [44,45]. Microinjections were carried out as
previously described [39]. Briefly, eGFP expression vec-
tors were injected into 1-2 cell stage embryos (n≥300).
Reporter expression was assayed between 24hpf-5dpf
and embryos with consistent GFP expression were
selected and raised to adulthood and founders were
identified. For morhpholino experiments, previously
published sox10 morpholino was ordered from Gene
Tools (Philomath, OR) [43]. 6.6 ng of the morpholino
was injected into each embryo by microinjection.
Embryos were analyzed and imaged using a Carl Zeiss
Lumar V12 Stereo microscope with AxioVision version
4.8 software. Transgenic lines for ERBB3_MCS1,
ERBB3_MCS4 and ERBB3_MCS3 are listed at the Zeb-
rafish International Resource Center (ZIRC) (http://zeb-
rafish.org) under allele designations JH112, JH113 and
JH114 respectively.
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Identification of conserved non-coding sequences and
transcription factor binding sites
Conserved sequences were identified at the human
ERBB3 locus and upstream and downstream intergenic
regions (chr12:54,724,274-54,784,370) using the Phast-
Cons custom track on the UCSC Genome Browser
(http://genome.ucsc.edu) on genome build hg18. We
used the 17-way MutiZ alignment to identify the most
conserved sequences within the introns of the gene and
within intergenic regions surrounding the gene. The
coordinates of the MCSs and the primers used to
amplify them are shown in Additional file 7, Table S1.
Fasta format DNA sequence of ERBB3_MCS6 from
the genome browser was used to query MatInspector
[46], MATCH 1.0 and Jaspar databases for identifiable
TFBS using default settings.
Vector construction and mutagenesis
Expression vectors were constructed using Gateway
Technology (Invitrogen, Carlsbad, CA). The desired
genomic regions were amplified by with attB-flanked
primers and recombined into the pDONR221 vector.
Successful recombination was confirmed by sequencing.
Next, entry clones were recombined into the destination
vectors pLGF-E1b for luciferase assays and pT2cfosGW
for zebrafish injections [25,47].
ERBB3_MCS6 was mutated using the QuikChange II
XL Site-directed mutagenesis kit (Stratagene, La Jolla,
CA). Mutagenesis primers were designed to change the
potential transcription factor binding sites (TFBS) to
Hpa1 restriction sites using the QuikChange Primer
Design tool. Primers are included in Additional file 8,
Table S2.
Sox10-pcDNA3.1 and Sox10-ΔSTP-pcDNA3.1 were
cloned using Sox10-pCMV and Sox10-ΔSTP-pCMV as
templates. Coding sequence for human SOX10 and AP2
for transactivation experiments was amplified by PCR
from I.M.A.G.E clone MGC-3510 and MGC-22117
respectively and cloned into pcDNA3.1 (Invitrogen,
Carlsbad, CA) using In-Fusion PCR Advantage Cloning
Kit (Clontech, Mountain View, CA). The PCR primers
used were designed using In-Fusion Primer Design tool
and are shown in Additional file 9, Table S3. Successful
cloning was verified by sequencing.
The E189X Sox10 cDNA cloned into a pCMV promo-
ter was a kind gift from Ken Inoue, Jim Lupski and
Michael Wegner [23,38].
Cell culture and transfection
Immortalized melanocytes (melan-a) and immortalized
Schwann cells were maintained as described [48,49].
NIH 3T3 cells were grown in 10% FCS in DMEM under
standard conditions. Neuro2A cells were grown in 10%
FCS in MEM under standard conditions.
Luciferase assay
melan-a cells were plated in 24-well plates 24 hours
prior to transfection at a density of 4 × 10^4 cells/well.
400 ng of the luciferase reporter plasmids were cotrans-
fected with 8 ng of CMV-RL renilla expression vector
(Promega, Madison, WI). 48 hours after transfection,
cell lysate was collected and assayed using the Dual-
Luciferase Reporter Assay System (Promega, Madison,
WI). For siRNA knockdown, 200 ng of luciferase repor-
ter vectors were cotransfected with 5 pmol of each
siRNA pool to a total of 10 pmol/well of a 24-well plate.
Where appropriate, scrambled siRNA was added to
maintain a final concentration of 10 pmol/well of
siRNA.
Neuro2A cells were plated in 24-well plates 24 hours
prior to transfection at a density of 5 × 10^4 cells/well.
400 ng of luciferase reporter plasmids were cotrans-
fected with 200 ng of Sox10-pcDNA3.1 and ΔSTP-
Sox10-pcDNA3.1. Where appropriate, empty pcDNA3.1
vector was added to maintain a final concentration of
800 ng/well of DNA. 8 ng of CMV-RL were added to
each well. Cell lysate was collected 24 hours after trans-
fection and assayed as mentioned above. Luciferase
assays were carried out using a Tecan GENiosPro
machine. All assays were performed in triplicate and
repeated in at least two independent experiments.
For luciferase assays in S16 cells, 1 × 10^4 cells were
plated in 96-well plates 24 hours prior to transfection
with luciferase vectors. Each transfection reaction
included 200 ng of experimental and control luciferase
expression constructs and 2 ng of a renilla expression
construct to control for transfection efficiency and cell
viability. Cells lysates were collected 48 hours after
transfection and luciferase assays were carried out with
the Dual-Luciferase Assay System (Promega, Madison,
WI) and analyzed on a Glomax Multi-Detection System
(Promega, Madison, WI).
siRNA knockdown
ON-TARGETplus SMARTpool siRNA was ordered
against mouse Sox10 and Tfap2a from Dharmacon
(Lafayette, CO). Knockdown was achieved by using 5
pmol of each siRNA in a 24-well transfection format.
Western blot
Cells were trypsinized and washed twice in 1XPBS and
resuspended in 2X Incomplete Lamelli buffer and passed
through a QiaShredder (Invitrogen, Carlsbad, CA) to
obtain whole cell lysate. Protein was quantified and run
on a 10% Mini Protean TGX gel (Biorad, Hercules, CA),
transferred onto a nitrocellulose membrane and blocked
overnight in 5% non-fat dry milk block. Sox10 antibody
was used at a dilution of 1.5 ng/ul (MAB2864, R&D Bio-
systems, Minneapolis, MN), AP2 antibody was used at
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1:500 (ab52222, Abcam, Cambrigde, MA), ErbB3 anti-
body was used at 1:500 (sc285, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) and anti-tubulin at 1:3000 (CP06,
Calbiochem, San Diego, CA). HRP-conjugated secondary
was used and antibody binding was visualized using
SuperSignal West Dura Extended Duration Substrate
(34076, Thermo Fischer, Rockford, IL). Membranes
were stripped using Restore PLUS Western Blot Strip-
ping Buffer (46430, Thermo Fischer, Rockford, IL
RNA extraction, cDNA synthesis and Real-time PCR
Neuro2A cells were plated in 6-well dish at a density of
2.5 × 10^5 cells/well using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA). A total of 2 ng of Sox10-pcDNA3.1
and ΔSTP-Sox10-pcDNA3.1 were transfected into the
cells and RNA was collected 24 hours later using the
RNeasy Mini Kit (Qiagen, Valencia, CA) using manufac-
turers instructions. Subsequently, cDNA was synthesized
using the SuperScriptIII First Strand Synthesis System
for RT-PCR (Invitrogen, Carlsbad, CA). Real-time PCR
was then performed in triplicate using the Universal
Gene Expression Master Mix (ABI, Carlsbad, CA) and
the PrimeTime qPCR Assay designed against mouse
Sox10 and ErbB3. Real-time PCR and analysis were per-
formed on the Opticon2 (Biorad, Hercules, CA).
Electrophoretic mobility shift assay
Probes spanning the SOXE-2 binding site were designed
(Additional file 10, Table S4) and labeled with the Biotin
3’ End DNA Labeling Kit (Pierce, Rockford, IL) accord-
ing to manufacturers instructions. Nuclear extract was
made from melan-a cells using the NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Pierce, Rockford, IL).
EMSAs were performed using the LightShift Chemilu-
minescent EMSA Kit (Pierce, Rockford, IL). Briefly, 12.5
fmol of labeled probe was incubated with nuclear
extract in the presence of binding buffer and 1 ug of
poly (dI.dC) in a 20 ul reaction for 10 min at room tem-
perature. For competition assays, 500 and 1000 molar
fold excess of unlabeled probe was added. Products
were run on precast polyacrylamide gels (4-20% or
7.5%) (Biorad, Hercules, CA) and signal was developed
using the LightShift Chemiluminescent kit.
Chromatin Immunoprecipitation (ChIP) and Real-time PCR
ChIP was performed in melan-a cells as previously
described [50] with some changes. Each ChIP experi-
ment was performed with ~1 × 108 cells. Alternative
lysis buffers to those in the referenced protocol were
used, as follows: Lysis buffer 1 (5 mM PIPES, 85 mM
KCl, 0.5% NP-40, and 1 × Roche Complete, EDTA-free
protease inhibitor), lysis buffer 2 (50 mM Tris-HCl, 10
mM EDTA, 1% SDS, and 1 × Roche Complete, EDTA-
free protease inhibitor), and lysis buffer 3 (16.7 mM
Tris-HCl, 1.2 mM EDTA, 167 mM NaCl, 0.01% SDS,
1.1% Triton X-100, and 1 × Roche Complete, EDTA-
free protease inhibitor). Sonication was performed with
a Bioruptor (Diagenode, Denville, NJ) with the following
settings: high output; 30 second disruption; 30 second
cooling; total sonication time of 35 min with addition of
fresh ice and cold water to water bath every 10 minutes.
2 ug of antibody specific to H3K4me1 (ab8895, Abcam
Cambridge, MA) and non-specific IgG (ab46540, Abcam
Cambridge, MA) was used for immunoprecipitation. IP
wash conditions were also adjusted from the above
referenced protocol, as follows: Each IP was washed
twice with low salt wash buffer (0.1% SDS, 1% Triton X-
100, 2 mM EDTA, 20 mM Tris-HCl, 150 mM NaCl),
twice with high salt wash buffer (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris-HCl, 500 mM NaCl),
twice with cold LiCl wash buffer (0.25M LiCl, 1% IGE-
PAL CA630, 1% deoxycholic acid (sodium salt), 1 mM
EDTA, 10 mM Tris-HCl), and rinsed once with PBS,
pH 7.4. Immunoprecipitated DNA was analyzed by real-
time PCR using SYBR Green (ABI, Carlsbad, CA) and
primers shown in Additional file 11, Table S4 and per-
formed and analyzed on an Opticon2 (Biorad, Hercules,
CA) using the % Input method. Primer sequences for
PCR are given in supplementary table 5.
ChIP in S16 cells was performed as previously
described [51]. The antibodies used were anti-Sox10 (sc-
17342X, Santa Cruz Biotechnology, Santa Cruz, CA)
and control anti-goat IgG (sc-2808, Santa Cruz Biotech-
nology, Santa Cruz, CA). ChIP was analyzed in duplicate
by quantitative PCR and analyzed by the % Input
method. Primers used for PCR are shown in Additional
file 11, Table S4.
Additional material
Additional file 1: Figure S1 - Identification of putative neural crest
transcription factor binding sites in ERBB3_MCS6. Sequence of
intronic neural crest enhancer ERBB3_MCS6 showing the location of
putative transcription factor binding sites (TFBS) identified using multiple
TFBS search programs. SOXE-2 adheres to the SOXE binding consensus
sequence.
Additional file 2: Figure S2 - Transcriptional transactivation of
ERBB3_MCS6 by SOX10 and AP2. Luciferase assay of wild type
ERBB3_MCS6 in NIH3T3 cells when transiently co-transfected with equal
amounts of an empty expression vector (pcDNA.31), SOX10 cDNA or AP2
cDNA. Cell lysates were collected 24 hours post transfection. All values
are normalized to a renilla internal control and shown as fold-change
compared to the promoter only construct (pe1B) with standard
deviation.
Additional file 3: Figure S3 - Increase in Sox10 transcript levels
upon Sox10 overexpression. Real-time PCR results showing an increase
in WT and mutant Sox10 cDNA upon transient transfection of WT and
Sox10-ΔSTP cDNA in Neuro2A cells. Values are normalized to an 18S
internal control and shown as a fold-change compared to the promoter
only construct (pcDNA3.1) with standard error.
Additional file 4: Figure S4 - A nuclear protein within melan-a cells
binds SOXE2. EMSA demonstrating binding of ERBB3_MCS6 to a protein
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in melan-a nuclei at the SOXE-2 site. Nuclear extract binds free probe
(Lane 1) and shifts it upwards (Lane 2). Addition of 500X (Lane 3) and
1000X (Lane 4) molar excess of unlabeled probes competes shift.
Addition of cold unlabeled probe with a mutation in the SOXE-2 binding
site does not compete away the shift (Lane 5).
Additional file 5: Figure S5 - ERBB3_MCS1 and ERBB3_MCS4 drive
reporter expression in vivo in a pattern similar to erbb3b. (A-J)
Expression pattern of the indicated MCS driving eGFP in G1 transgenic
24-72hpf zebrafish embryos. Arrows indicate tissues where expression
was noted in multiple founders. Abbreviations: mesencephalon (M),
hindbrain (HB), olfactory bulb (OB), pharyngeal arches (PA), cranial
ganglia, posterior lateral line ganglia (PLLg).
Additional file 6: Figure S6- Range of eGFP phenotypes in
ERBB3_MCS6 transgenic fish upon sox10 morpholino injection. (A-B)
eGFP expression driven by ERBB3_MCS6 in uninjected fish at 24hpf.
Expression is noted in cranial neural crest (CNC), premigratory NC (PMC)
and migratory crest (MC) (C-D) Fewer eGFP positive CNC (C) and PMC
cells seen in sox10 morpholino injected transgenic embryos, and
significantly reduced numbers of MC (D).
Additional file 7: Table S1- Coordinates of the ERBB3_MCS8
elements (human genome build hg18) and primers used for PCR
amplification of each element.
Additional file 8: Table S2- Primers used for site-directed
mutagenesis of ERBB3_MCS6.
Additional file 9: Table S3- Primers used for cloning WT and mutant
sox10 cDNA, AP2 and SOX10 cDNA.
Additional file 10: Table S4- Probes used for EMSA assay.
Additional file 11: Table S5- Primers used for qPCR analysis of ChIP
assay.
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